URGN Share Price Performance
US$0
-18.24 (-100.00%)
Price US$0
Fair ValueUS$36.11
Share Pricen/a
Analysis Article • Aug 07
UroGen Pharma Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
URGN Community Narratives
AN
Fair Value
·Fair Value US$36.11 28.2% overvalued intrinsic discount
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
0users have liked this narrative
0users have commented on this narrative
14users have followed this narrative
AN
Fair Value
·Fair Value US$45 2.9% overvalued intrinsic discount
Aging Demographics And Advanced Therapies Will Reshape Urology Practice
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$40 15.8% overvalued intrinsic discount
Stricter FDA Oversight And Pricing Pressures Will Limit Reach
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Stricter FDA Oversight And Pricing Pressures Will Limit Reach
UroGen Pharma’s growth story hinges on new bladder-cancer treatments, but tougher drug oversight and pricing pushback could slow launches and limit how widely its newest product is used. With so much depending on just a couple of medicines—and the need to keep raising money—small setbacks or faster-moving rivals could quickly change the outlook.Read more
AN
US$40
15.8% overvalued intrinsic discount
Fair Value
Profit Margin
35.51%
Future PE
13.56x
Price in 2029
US$48.55
Aging Demographics And Advanced Therapies Will Reshape Urology Practice
UroGen bets that many urologists are ready to move patients away from surgery as reimbursement becomes easier for its newer treatment, which could quickly change how this condition is treated. The big question is whether those two main products can scale fast enough to outrun ongoing losses, payer pushback, and tougher competition.Read more
AN
US$45
2.9% overvalued intrinsic discount
Fair Value
Profit Margin
58.18%
Future PE
8.19x
Price in 2029
US$54.8
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
Key Takeaways Successful ZUSDURI launch and pipeline expansion position UroGen for significant revenue growth and reduced product dependency. Alignment with industry care trends and robust commercialization strategy support premium pricing and improved long-term profitability.Read more
AN
US$36.11
28.2% overvalued intrinsic discount
Fair Value
Profit Margin
32.29%
Future PE
14.71x
Price in 2029
US$44.43
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
URGN: Patent Duration And Bladder Cancer Franchise Will Shape Balanced Upside Potential
Fair Value: US$40 15.8% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
URGN: Future Bladder Cancer Trial Milestones May Reframe Long Term Upside Potential
Fair Value: US$45 2.9% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
URGN: Future Profit Margins Will Improve Through LG UTUC Trial Momentum
Fair Value: US$36.11 28.2% overvalued intrinsic discount
14 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
UroGen Pharma Ltd. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -2.00
- 90.85%
- -51.73%
- -142.6%
About URGN
- Founded
- 2004
- Employees
- 300
- CEO
- WebsiteView website
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Recent URGN News & Updates
Narrative Update • Jul 30
